A recent report identified that PRMT5 is overexpressed in MCL, and application of PRMT5 specific inhibitor PRT382 was found to reduce tumor burden in an ibrutinib-resistant MCL-PDX mouse model [180]. The gene discussed is PRMT5; the disease is mantle cell lymphoma.